-
Patent Agency Ranking
公开(公告)号：WO2010050783A2
公开(公告)日：2010-05-06
申请号：PCT/KR2009/006357
申请日：2009-10-30
IPC: C07D493/10 , C07D493/04 , C07D493/02 , A61K31/35 , A61K31/36 , A61P19/10
CPC classification number: C07D493/10
Abstract: 본 발명은 스파이로키랄 탄소 골격을 갖는 신규한 화합물, 그의 입체이성질체, 그의 거울상이성질체, 생체 내에서 가수분해 가능한 그의 전구체 또는 약제학적으로 허용 가능한 그의 염을 제공한다. 상기 스파이로키랄 탄소 골격을 갖는 신규한 화합물은 조골세포 분화능이 우수하며, 비만세포 분화억제능 및 간에서의 지방산 합성 억제능을 가지므로, 골다공증, 지방간 및 비만치료에 획기적인 역할을 할 것으로 기대된다.
Abstract translation:
本发明提供了新颖的化合物，它们的立体异构体，其对映体，其在体内可水解前体，或具有间谍洛基LAL碳骨架的药物上可接受的盐。 具有间谍洛基LAL碳骨架和成骨细胞多能的新化合物是优异的，因为的肥大细胞分化的抑制能力的脂肪酸合成的抑制能力，和肝，预计是在骨质疏松症，脂肪肝和肥胖症的一个创新的作用。< / p>
-
公开(公告)号：KR101149878B1
公开(公告)日：2012-05-24
申请号：KR1020090104124
申请日：2009-10-30
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , C07D493/02 , A61K31/435 , A61P3/04
CPC classification number: C07D493/10
Abstract: Provided are a novel compound with a spiro chiral carbon backbone, a stereoisomer thereof, an enantiomer thereof, an in vivo hydrolysable precursor thereof, or a pharmaceutically acceptable salt thereof. The novel compound with the spiro chiral carbon backbone has excellent osteoblast differentiation activity, mast cell inhibitoryactivity, and fatty acid synthesis inhibitory activity in the liver. Therefore, the novel compound can be expected to play an innovative role in treatment of osteoporosis, fatty liver, and obesity.
-
公开(公告)号：KR1020120025440A
公开(公告)日：2012-03-15
申请号：KR1020110090896
申请日：2011-09-07
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , A61K31/352 , A61P3/10 , A61P9/00
CPC classification number: C07D493/10 , A61K31/352 , A61K31/4184 , A61K31/4192 , A61K31/422 , A61K31/453 , A61K31/496 , A61K31/541 , A61K31/665 , A61K31/7048 , A61K45/06 , C07D493/20 , C07F9/65615 , C07H17/04
Abstract: PURPOSE: A sesterterpen compound and a composition containing the same are provided to prevent and treat diabetes, fatty liver, and obesity. CONSTITUTION: A sesterterpen compound is denoted by chemical formula I. A pharmaceutical composition for preventing and treating diabetes, diabetes complication, cardiovascular diseases or obesity contains sesterterpen compounds, stereoisomer, enantiomer, hybridizable precursor, or pharmaceutically acceptable salt thereof. A pharmaceutical composition for preventing and treating cardiovascular diseases contains sesterterpen compounds of chemical formula I, stereoisomer, enantiomer, in vivo hybridizable precursor thereof, or pharmaceutically acceptable salt thereof, and LXR agonist.
Abstract translation: 目的：提供西酯化合物和含有它们的组合物以预防和治疗糖尿病，脂肪肝和肥胖。 构成：化学式I表示酯化合物。用于预防和治疗糖尿病，糖尿病并发症，心血管疾病或肥胖症的药物组合物含有酯化合物，立体异构体，对映异构体，可杂交前体或其药学上可接受的盐。 用于预防和治疗心血管疾病的药物组合物含有化学式I的酯化合物，立体异构体，对映异构体，体内可杂交的前体或其药学上可接受的盐和LXR激动剂。
-
公开(公告)号：KR1020100048934A
公开(公告)日：2010-05-11
申请号：KR1020090104124
申请日：2009-10-30
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , C07D493/02 , A61K31/435 , A61P3/04
CPC classification number: C07D493/10
Abstract: PURPOSE: A novel compound having spiro chiral carbon skeleton is provided to suppress mastocyte differentiation and fatty acid synthesis and use in treating osteoporosis, fatty liver, and obesity. CONSTITUTION: A novel compound having spiro chiral carbon skeleton is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of cutting and drying Phorbas sp. and extracting with C1-C4; a step of dividing the extracting with water and methylene chloride to remove solvent of organic layer; a step of distributing with mixture solution of normal hexane, methanol, and water; a step of removing solvent of methanol layer; and a step of performing chromatography to obtain fraction.
Abstract translation: 目的：提供一种具有螺状手性碳骨架的新型化合物，用于抑制肥大细胞分化和脂肪酸合成，并用于治疗骨质疏松症，脂肪肝和肥胖症。 构成：具有螺状手性碳骨架的新化合物由化学式1表示。化学式1化合物的制备方法包括：切割并干燥佛波斯 并用C1-C4提取; 用水和二氯甲烷分离提取物以除去有机层的溶剂的步骤; 用正己烷，甲醇和水的混合溶液分配的步骤; 去除甲醇层溶剂的步骤; 以及进行色谱以获得级分的步骤。
-
公开(公告)号：KR101901741B1
公开(公告)日：2018-10-01
申请号：KR1020110090896
申请日：2011-09-07
Applicant: 서울대학교산학협력단
IPC: C07D493/10 , A61K31/352 , A61P3/10 , A61P9/00
CPC classification number: C07D493/10 , A61K31/352 , A61K31/4184 , A61K31/4192 , A61K31/422 , A61K31/453 , A61K31/496 , A61K31/541 , A61K31/665 , A61K31/7048 , A61K45/06 , C07D493/20 , C07F9/65615 , C07H17/04
Abstract: 본발명은세스터터핀화합물, 생체내에서가수분해가능한그의전구체또는약제학적으로허용가능한그의염 및세스터터핀화합물이갖는인슐린비의존성당뇨병, 당뇨합병증(당뇨병에의한신부전증및 족부궤양증), 알콜성, 비알콜성및 바이러스성지방간질환, 비만, 고지혈증, 동맥경화증(atherosclerosis), 동맥경화성중품과같은심혈관계질환, 뇌질환(파킨슨병, 조울증, 정신분열증및 알츠하이머병)에대한예방및 치료효능에관한것이다. 또한본 발명은이들물질의기능성식품, 기능성음료, 기능성화장품및 기능성사료의조성물제공에관한것이다. 본발명의세스터터핀화합물은당뇨병과더불어지방간, 비만외에도고지혈증, 동맥경화증과같은심혈관계질환예방및 치료에우수한효능이있다. 또한저밀도콜레스테롤(LDL) 감소와대식세포유래염증사이토카인및 간에서의지방생합성효소의발현억제를통하여기존핵수용체 LXR 활성물질(agonists)와복합제제로고지혈증, 동맥경화와심혈관계질환을예방및 치료할수 있다. 더욱이신경세포의도파민항상성에관여하는단백질을활성화하여단일제제로파킨슨병, 조울증및 정신분열증을예방치료제로사용할수 있다. 또한본 발명의화합물은기존 LXR 활성물질의부작용인지방간을억제함으로써, 알츠하이머병예방및 치료효능이알려져있는문헌에보고된핵수용체 LXR 활성물질(agonists)와복합제제로알츠하이머병예방및 치료제로서사용될수 있다. 또한, Nurr1 활성물질로써알츠하이머와더불어파킨슨병및 치매(dementia)과같은뇌질환예방및 치료제로이용가능하다.
-
-
-
-
Search Results
5
records
(took 0.016 seconds)
